An interventional study of Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B and Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A in Pancreatic Cancer, Adult and Cephalic Duodenopancreatectomy, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Malnutrition is a common challenge in patients with pancreatic cancer undergoing cephalic pancreaticoduodenectomy (CPD), impacting postoperative recovery and overall prognosis. Nutritional support plays a crucial role in optimising metabolic, inflammatory, and digestive outcomes. This randomised, double-blind, crossover clinical trial aims to evaluate the effects of Peptamen 1.6, a hydrolysed whey protein-based enteral formula, compared to Resource HP/HC, a high-protein and high-calorie polymeric formula, in malnourished or at-risk patients with pancreatic cancer undergoing PD.
The study comprises both in vivo and in vitro analyses. The in vivo component will assess the impact of Peptamen 1.6 on digestive tolerance, amino acid absorption, nutritional status, metabolic profile, inflammatory markers, and gut microbiota composition. The in vitro component will utilise human intestinal organoid models to explore how enteral nutrition formulations influence intestinal permeability and metabolism, with a focus on microbiota interactions.
Primary outcomes include improvements in metabolic status, assessed through serum biomarkers (albumin, immune markers, intestinal permeability, and myosin profile), inflammatory status via peripheral blood mononuclear cells (PBMCs), and microbiota shifts in faecal samples. Additionally, adherence to treatment, digestive tolerance, and changes in body composition will be monitored using bioelectrical impedance, dynamometry, and functional mobility tests.
By elucidating the mechanisms through which different enteral nutrition strategies influence clinical, physiological, and molecular parameters, this study aims to enhance personalised nutritional interventions for patients with pancreatic cancer. The findings could contribute to optimising nutritional support strategies, ultimately improving patient outcomes following CPD.
25 studies on the registry are indexed under Pancreatic cancer, adult; 18 are open to participants now.
This study's planned enrollment of 20 is below the median of 90 across 17 interventional studies indexed under Pancreatic cancer, adult.
Browse Pancreatic cancer, adult studies →Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud is the lead sponsor of 72 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B
Dietary Supplement: Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A
Intervention group will receive a nutritional formula A and, after 1-week washout period, will receive a nutritional formula B
Intervention group will receive a nutritional formula B and, after 1-week washout period, will receive a nutritional formula A
Adherence to nutritional treatment
Categorized based on the average daily consumption compared to the prescribed volume (200 ml per bottle): * Full content (200 ml/bottle) * 2/3 content (150 ml/bottle) * 1/2 content (100 ml/bottle) * 1/4 content (50 ml/bottle) Patients will self-report their average daily consumption (ml/day).
Time frame: At weeks 6 and 13
Natural food intake
Patients will report their food intake over the previous week, categorized into quartiles (%) relative to: * Pre-illness consumption * Perceived normal intake for patients without supplementation * ALL -100% * 3/4 - 75% * HALF - 50% * ¼ - 25% * NONE - 0%
Time frame: At weeks 6 and 13
Tolerance to nutritional treatment
Evaluated based on the frequency of gastrointestinal symptoms (e.g., nausea, vomiting, reflux, abdominal pain, flatulence, satiety, constipation, and stomach heaviness) within two hours of supplement consumption. Symptoms classified as: * Never * Rarely * Sometimes * Frequently * Always Bivariate analysis will classify tolerance as: * Good (no symptoms) * Poor (presence of any gastrointestinal symptoms)
Time frame: At weeks 6 and 13
Change in aminoacids: Ala, Glu, Asp, Pro, Phe, Leu/Ile, Val, Tyr, Met, Cit, Arg, Gly, and Orn
Aminoacids measured in µmol/L
Time frame: At baseline and in weeks 6, 7, and 13
Change in IL-6 and TNF-alpha RNA expression
IL-6 and TNF-alpha measured from Peripheral blood mononuclear cell (PBMC)
Time frame: At baseline and in weeks 6, 7, and 13
Doses of pancreatic enzyme replacement therapy
Measured in International Unit per day (IU/day)
Time frame: Only at baseline
Stool characteristics
The number and type of stools will be assessed using the Kings Stool Chart, a standardized tool that classifies stool consistency and form to evaluate digestive function alterations. * Number of bowel movements: A numerical field to record the daily count. * Type of bowel movements: A categorical field with options ranging from 1 to 7, based on the King's Stool Chart. * Variability in type: A binary field (0 = No, 1 = Yes) to indicate whether there is variation.
Time frame: At baseline and in weeks 6, 7, and 13
Symptoms of anxiety and depression
Measured using the Hospital Anxiety and Depression Scale (HADS), which consists of two subscales: HADS-Anxiety (HADSA) and HADS-Depression (HADSD) Interpretation of scores: * 0-7: Normal. * 8-10: Suggests the presence of mood disorders. * ≥11: Indicates a probable mood disorder.
Time frame: At baseline and in weeks 6, 7, and 13
Nutritional status
Evaluated using the Subjective Global Assessment (SGA) and Global Leadership Initiative on Malnutrition (GLIM) criteria, both validated tools for classifying malnutrition severity. Patients will be categorized as at risk of malnutrition or having moderate or severe malnutrition based on results.
Time frame: At baseline and in weeks 6, 7, and 13
Change in Phase angle (PhA) (Vectorial Bioimpedance Analysis (BIVA))
Phase angle (PhA) measured in degrees (º)
Time frame: At baseline and in weeks 6, 7, and 13
Change in total body water (TBW) (Vectorial Bioimpedance Analysis (BIVA))
Total body water (TBW) measured in liters (l)
Time frame: At baseline and in weeks 6, 7, and 13
Change in extracellular water (ECW) (Vectorial Bioimpedance Analysis (BIVA))
Extracellular water (ECW) measured in liters (l)
Time frame: At baseline and in weeks 6, 7, and 13
Change in intracellular water (ICW) (Vectorial Bioimpedance Analysis (BIVA))
Intracellular water (ICW) measured in liters (l)
Time frame: At baseline and in weeks 6, 7, and 13
Change in Fat-free mass (FFM) (Vectorial Bioimpedance Analysis (BIVA))
Fat-free mass (FFM) measured in kilograms (kg) and percentage (%)
Time frame: At baseline and in weeks 6, 7, and 13
Change in Fat mass (FM) (Vectorial Bioimpedance Analysis (BIVA))
Fat mass (FM) measured in kilograms (kg) and percentage (%)
Time frame: At baseline and in weeks 6, 7, and 13
Change in Body cell mass (BCM) (Vectorial Bioimpedance Analysis (BIVA))
Body cell mass (BCM) measured in kilograms (kg)
Time frame: At baseline and in weeks 6, 7, and 13
Change in appendicular skeletal muscle mass (ASMM) (Vectorial Bioimpedance Analysis (BIVA))
Appendicular skeletal muscle mass (ASMM) measured in kilograms (kg)
Time frame: At baseline and in weeks 6, 7, and 13
Change in skeletal muscle index (SMI) (Vectorial Bioimpedance Analysis (BIVA))
Skeletal muscle index (SMI) measured in kilogram per square meter (kg/m²)
Time frame: At baseline and in weeks 6, 7, and 13
Change in hydration (Vectorial Bioimpedance Analysis (BIVA))
Hydration measured in percentage (%)
Time frame: At baseline and in weeks 6, 7, and 13
Change in resistance (Vectorial Bioimpedance Analysis (BIVA))
Resistance measured in ohms (Ω)
Time frame: At baseline and in weeks 6, 7, and 13
Change in reactance (Vectorial Bioimpedance Analysis (BIVA))
Reactance measured in ohms (Ω)
Time frame: At baseline and in weeks 6, 7, and 13
Handgrip dynamometry
* Device: Jamar hydraulic dynamometer * Measurement: Mean and maximum grip strength (kg) from three measurements Used to assess sarcopenia
Time frame: At baseline and in weeks 6, 7, and 13
Timed Up and Go (TUG) Test
* Measures mobility and physical function * Procedure: Time (seconds) taken for the patient to: 1. Rise from a chair 2. Walk a short distance 3. Return to the chair
Time frame: At baseline and in weeks 6, 7, and 13
Change in total fat (Abdominal Ultrasound)
Total fat measured in centimeters (cm)
Time frame: At baseline and in weeks 6, 7, and 13
Change in superficial fat (Abdominal Ultrasound)
Superficial fat measured in centimeters (cm)
Time frame: At baseline and in weeks 6, 7, and 13
Change in preperitoneal fat (Abdominal Ultrasound)
Preperitoneal fat measured in centimeters (cm)
Time frame: At baseline and in weeks 6, 7, and 13
Change in muscle Ultrasound - Area
Area measured in square centimeters (cm²)
Time frame: At baseline and in weeks 6, 7, and 13
Change in muscle Ultrasound - Circumference
Circumference measured in centimeters (cm)
Time frame: At baseline and in weeks 6, 7, and 13
Change in muscle Ultrasound - X-axis and Y-axis
X-axis and Y-axis measured in centimeters (cm)
Time frame: At baseline and in weeks 6, 7, and 13
Change in muscle Ultrasound - Adipose tissue of the rectus femoris of the quadriceps
Adipose tissue of the rectus femoris of the quadriceps measured in centimeters (cm)
Time frame: At baseline and in weeks 6, 7, and 13
Change in Glucose
glucose measured in mg/dl
Time frame: At baseline and in weeks 6, 7, and 13
Change in Cholesterol
Cholesterol measured in mg/dl
Time frame: At baseline and in weeks 6, 7, and 13
Change in Triglycerides
Triglycerides measured in mg/dl
Time frame: At baseline and in weeks 6, 7, and 13
Change in Uric acid
Uric acid measured in mg/dl
Time frame: At baseline and in weeks 6, 7, and 13
Change in AST
AST measured in units per litre (U/L)
Time frame: At baseline and in weeks 6, 7, and 13
Change in ALT
ALT measured in units per litre (U/L)
Time frame: At baseline and in weeks 6, 7, and 13
Change in GGT
GGT measured in units per litre (U/L)
Time frame: At baseline and in weeks 6, 7, and 13
Change in ALP
ALP measured in units per litre (U/L)
Time frame: At baseline and in weeks 6, 7, and 13
Change in insulin
Insulin measured in units per mililitre (U/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in albumin
Albumin measured in grams per liter (g/l)
Time frame: At baseline and in weeks 6, 7, and 13
Change in C-reactive protein (CRP)
C-reactive protein (CRP) measured in milligrams per liter (mg/L)
Time frame: At baseline and in weeks 6, 7, and 13
Change in Intestinal fatty acid-binding protein (I-FABP)
Intestinal fatty acid-binding protein (I-FABP) measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in zonulin
Zonulin measured in micrograms per milliliter (μg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in musclin
Musclin measured in nanograms per milliliter (ng/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in galectin-3
Galectin-3 measured in nanograms per milliliter (ng/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in myostatin
Myostatin measured in nanograms per milliliter (ng/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in Total antioxidant capacity (TAC)
Total antioxidant capacity (TAC) measured in nanomoles per microliter (nmol/μL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in Glutathione peroxidase (GSH-Px)
Glutathione peroxidase (GSH-Px) measured in milliunits per milliliter (mU/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in Superoxide dismutase (SOD)
Superoxide dismutase (SOD) measured in inhibition rate %
Time frame: At baseline and in weeks 6, 7, and 13
Change in GLP-1
GLP-1 measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in GIP
GIP measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in PYY
PYY measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in IFN-gamma
IFN-gamma measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in IL-2
IL-2 measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in IL-4
IL-4 measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in IL-6
IL-6 measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in IL-10
IL-10 measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in IL-12p70
IL-12p70 measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in IL-17A
IL-17A measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in TNF-alpha
TNF-alpha measured in picograms per milliliter (pg/mL)
Time frame: At baseline and in weeks 6, 7, and 13
Change in stool calprotectin
Calprotectin measured in micrograms per gram (µg/g)
Time frame: At baseline and in weeks 6, 7, and 13
Plan to share: No — It is not necessary to reach the objectives of the project
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud